^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Purinergic receptor P2Y12 inhibitor

    Related drugs:
    2d
    DAPTCLTI: Duration of Dual Anti-Platelet Therapy in Chronic Limb Threatening Ischemia After Distal Revascularization (clinicaltrials.gov)
    P3, N=614, Not yet recruiting, Fondation Hôpital Saint-Joseph
    New P3 trial
    3d
    STOP-IMH (2024-517783-37-00)
    P4, N=200, Recruiting, Radboud universitair medisch centrum Stichting | Not yet recruiting --> Recruiting
    Enrollment open
    6d
    STREAMLINE: Dual Antiplatelet Therapy Strategies After Acute Myocardial Infarction Undergoing PCI: Prasugrel vs Ticagrelor & 12 Months vs 1-3 Months (clinicaltrials.gov)
    P4, N=8100, Not yet recruiting, Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
    New P4 trial
    8d
    Mechanisms fo Clopidogrel Resistance in Older Adults (CEPAGE) (clinicaltrials.gov)
    P=N/A, N=37, Completed, Rennes University Hospital | Recruiting --> Completed | N=100 --> 37
    Trial completion • Enrollment change
    19d
    TIMO: Ticagrelor Monotherapy After Stenting (clinicaltrials.gov)
    P2, N=200, Completed, Vastra Gotaland Region | Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Jun 2025
    Trial completion • Trial completion date
    22d
    Ticagrelor reverses multidrug resistance in breast cancer by inhibiting PI3K/AKT/mTOR pathway and suppressing ABCB1 expression and function. (PubMed, Biochem Pharmacol)
    Ticagrelor synergistically enhanced the cytotoxicity of Adriamycin (Adr) and Paclitaxel (PTX) in MCF-7/Adr and MCF-7/PTX cells, respectively. In conclusion, Ticagrelor reverses breast cancer MDR by concurrently inhibiting PI3K/AKT/mTOR signaling, downregulating ABCB1 expression and function. Our findings highlight the potential of Ticagrelor as a dual-acting agent that not only targets tumor metastasis but also overcomes chemoresistance, providing a new strategic direction for combination therapy in refractory breast cancer.
    Journal
    |
    ABCB1 (ATP Binding Cassette Subfamily B Member 1)
    |
    paclitaxel • doxorubicin hydrochloride
    30d
    STAR-TEER: STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients With an Indication for Oral Anticoagulant (clinicaltrials.gov)
    P4, N=880, Recruiting, Chinese Academy of Medical Sciences, Fuwai Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    1m
    TAILOR BLEED: Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI (clinicaltrials.gov)
    P4, N=90, Recruiting, University of Florida | Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Jan 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    1m
    EPIDAURUS: Escalated Single Platelet Inhibition for One Month Plus NOAC in Patients With Atrial Fibrillation and ACS Undergoing PCI (clinicaltrials.gov)
    P4, N=2334, Completed, Ludwig-Maximilians - University of Munich | Active, not recruiting --> Completed
    Trial completion
    1m
    CAPTIVA: Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis (clinicaltrials.gov)
    P3, N=1683, Recruiting, University of Florida | Active, not recruiting --> Recruiting
    Enrollment open
    1m
    REPERFUSE: REperfusion With P2Y12 Inhibitors in Addition to mEchanical thRombectomy for perFUsion Imaging Selected Acute Stroke patiEnts (clinicaltrials.gov)
    P3, N=368, Recruiting, Fondation Ophtalmologique Adolphe de Rothschild | Trial completion date: Jan 2027 --> Sep 2030 | Trial primary completion date: Mar 2026 --> Mar 2030
    Trial completion date • Trial primary completion date
    1m
    Comparative Bioavailability Study Between Ticagrelor and ASA Administered Individually or in Combination. (clinicaltrials.gov)
    P1, N=24, Completed, Laboratorios Silanes S.A. de C.V.
    New P1 trial
    |
    aspirin